← Back to Portfolio
Soteria
Soteria is developing next-generation small-molecule-activated ‘protein switches’ for controlling the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.
Soteria is developing next-generation small-molecule-activated ‘protein switches’ for controlling the activity of immunomodulatory therapeutics such as bi-specific T-cell engagers (BiTEs) and CAR T-cells.